Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

cinomas carrying the erlotinib-resistant mutation EGFR L858R/T790M. These in vivo results suggest that AV-412 may exert potent clinical activity against non-small cell lung cancer tumors harboring EGFR L858R or EGFR L858R/T790M mutations.

About AV-412

AV-412 is a next generation oral tyrosine kinase inhibitor of EGFR/HER2 that could potentially treat patients with solid tumors. In preclinical studies, AV-412 has shown excellent activity in various tumor models, has a toxicity profile similar to other molecules in its class, and has shown preclinical activity against tumor cells that are resistant to first-generation tyrosine kinase inhibitors. The targets of AV-412 have been implicated in many significant human cancers including non-small cell lung cancer, metastatic breast cancer, pancreatic cancer, head and neck cancer and hormone refractory prostate cancer. AVEO's proprietary Human Response Prediction(TM) Platform offers an opportunity to exploit AV-412's unique characteristics and will provide further insight into potential clinical settings, tumor subtypes and responsive patient populations. AVEO acquired worldwide rights outside of Asia to AV-412 from Mitsubishi Pharma Corporation. For more information on the AV-412 clinical trial, visit www.clinicaltrials.gov and search using the keyword AV-412.

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by Q3-2007 for AV-951, its oral, second-generation VEGF receptor inhibit
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:4/21/2015)... 2015  St. Vincent Healthcare is raising the ... following strict disinfection routines, St. Vincent Healthcare is now ... harmful germs, like Ebola, methicillin-resistant Staphylococcus aureus ... infect patients during their hospital stay. ... - http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
(Date:4/21/2015)... 21, 2015  IntelliQuit™, the world,s first smartphone breathalyzer for smokers, was selected to present as ... New York City on Wednesday April 22.  ... ... ... Thirty percent (30%) of all cardiovascular disease is caused ...
(Date:4/21/2015)...  Navitas has launched Aviator, a Cloud Based Platform ... for life sciences clients. Aviator supports Regulatory, Clinical and ... flow of data across all applications and into the ... closely with Oracle to provide Argus, Life Sciences Data ... Cloud. ...
Breaking Medicine Technology:St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 2Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 4
(Date:4/21/2015)... 2015 The report “Sinusitis ... analysis on the therapeutic development for Sinusitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Sinusitis ...
(Date:4/21/2015)... Information is the best weapon in the fight ... patients and their families with knowledge about living with cancer ... is the Answer" and new website . , In ... patients from diagnosis through treatment and even death. The goal, ... treatment, at home and in the examination room. , “Cancer ...
(Date:4/21/2015)... 2015 Lyft has announced the ... otolaryngologists, bringing the most advanced speech-recognition technology to ... Otolaryngologists can now experience the full benefits of ... in the industry, Lyft, which offers value-added support ... , “Lyft is very excited to be able ...
(Date:4/21/2015)... On April 8th, 2015, Choices Recovery ... the world famous Avalon Hollywood. Organized by Debbie Durkin, ... TV and film, the EcoLuxe Lounge is a premier ... ceremonies and festivals throughout the year. A gathering of ... socially conscious products and services, this daylong event is ...
(Date:4/21/2015)... Colmar, PA (PRWEB) April 21, 2015 ... Ichthyosis & Related Skin Types, Inc.® (FIRST) will publish ... ichthyosis. The campaign will run throughout the month of ... Voice. It Matters to Someone." The positioning was ... about this rare skin disorder and to help support ...
Breaking Medicine News(10 mins):Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2
... Insured or not, patients forgo medical needs twice as ... 4 (HealthDay News) -- Unmanageable health-care costs are forcing ... United States to go without the medical attention they ... study indicates that Hispanic and African-American cancer survivors are ...
... Annual Scientific Meeting in Chicago, IL, on April 25-30, ... meeting of urologic professionals in the world, and is ... from around the world. This year, more than 2,000 ... will showcase their products and services in the Science ...
... Feb. 4 Franklin & Seidelmann,( http://www.franklin-seidelmann.com ... penetration into the hospital sector with the,addition of three ... , -- Barnes-Kasson Hospital, Susquehanna, PA, ... KY, -- Syringa General Hospital, Grangeville, ...
... world seeks new ways to prevent and treat chronic diseases ... to be conducted on the benefits of certain foods in ... are often cited as being high in antioxidants, which have ... cells within the body, reducing the risk of cancer and ...
... Excellent Source of Omega-3s EPA/DHA and 170% Daily Requirement of ... SMBL ) today announced that it will launch ... and Albany metro areas and New England during the first ... varieties and currently sold in Florida and Georgia, tastes rich ...
... chief architect of BurrellesLuce 2.0, will be the featured speaker at ... Society of America. , ... Livingston, NJ (PRWEB) February 4, 2009 -- ... 2.0 , will be the featured speaker at the Feb. 11th ...
Cached Medicine News:Health News:Cancer Survivors Say Costs Keep Them From Care 2Health News:Cancer Survivors Say Costs Keep Them From Care 3Health News:Cancer Survivors Say Costs Keep Them From Care 4Health News:Franklin & Seidelmann Expands into Critical Access Hospital Market Provides 24 x 7 Teleradiology Service for Three New Clients 2Health News:Franklin & Seidelmann Expands into Critical Access Hospital Market Provides 24 x 7 Teleradiology Service for Three New Clients 3Health News:Dry beans inhibit development of mammary cancer 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 3Health News:BurrellesLuce IT Expert to Explore Web 3.0's Potential PR Impact At February Luncheon Meeting of Westchester/Fairfield PRSA 2Health News:BurrellesLuce IT Expert to Explore Web 3.0's Potential PR Impact At February Luncheon Meeting of Westchester/Fairfield PRSA 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: